PITTSBURGH , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that the United States Patent Office (USPTO) has granted U.S. Patent No.

PITTSBURGH , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” topical and intra-dermal treatments for dermatological diseases, today reported financial results for the third quarter ended September 30, 2017 , and provided an

PITTSBURGH, Pa. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S.

PITTSBURGH, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has received an equity-based award totaling $770,000

PITTSBURGH , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the closing of its initial public offering of

PITTSBURGH , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”)(Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced a presentation of preclinical data assessing the

PITTSBURGH, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the pricing of its initial public offering.